Stand Up To Cancer - standuptocancer.orgThis is where the end of cancer begins
   Please leave this field empty

SU2C Scientific Research Teams

Share this:
Email

Like this page on Facebook

Maximilian Diehn, MD, PhD

Scientific Research Team:
Maximilian Diehn, MD, PhD

Maximilian Diehn, MD, PhD

Maximilian Diehn, MD, PhD, co-leader of the SU2C-LUNGevity Foundation-American Lung Association Lung Cancer Interception Translational Research Team, is an assistant professor of radiation oncology with co-appointments in the Stanford Cancer Institute and Institute for Stem Cell Biology and Regenerative Medicine.  He is an expert in lung cancer, cancer genomics, and circulating nucleic acids. His current research efforts are focused on developing improved methods for treating and monitoring cancers. In the laboratory, he focuses on genomics-based biomarker development and biology of normal and malignant epithelial stem cells. His group employs tools from genomics, bioinformatics, stem cell biology, and mouse genetics. A major focus is analysis of circulating tumor DNA using an ultra-sensitive and specific method called CAPP-Seq, which he co-developed. The method was developed specifically for lung cancer and is being applied to a wide range of clinical questions, ranging from early detection to advanced disease.